AR101 – Enzastaurin
Enzastaurin Clinical Development
Prevention of Rupture with Enzastaurin in Vascular Ehlers-Danlos Syndrome
To register to receive more information about the planned PREVEnt Trial, click the button below
Objective: To evaluate the efficacy of enzastaurin compared to placebo in preventing arterial events leading to intervention in patients with Vascular Ehlers-Danlos Syndrome (VEDS) confirmed with COL3A1 gene mutations.
Upcoming Clinical Trial
Aytu BioPharma, Inc. will be sponsoring an upcoming clinical trial to evaluate the effectiveness of AR101 (enzastaurin) in preventing cardiac or arterial events in patients with Vascular Ehlers-Danlos Syndrome (VEDS) confirmed with COL3A1 gene mutations, compared to placebo. Please register to receive important updates concerning this trial.
About Vascular Ehlers-Danlos Syndrome (VEDS)
Vascular Ehlers-Danlos Syndrome (VEDS) is an inherited connective tissue disorder, typically caused by a mutation in the COL3A1 gene. This mutation leads to defects in type III procollagen, a major protein in vessel walls and hollow organs. Patients with this diagnosis are at significant risk for serious vascular events like dissections, pseudoaneurysms, and ruptures throughout the vasculature.
VEDS affects about 1 in 50,000 people worldwide. Nearly 50% of patients with this devastating condition die before the age of 50 years old. Currently, there are no FDA-approved therapies, and after diagnosis, the current standard of care is “watchful waiting.”
About AR101 (enzastaurin)
Scientific Advisory Board
Hal Dietz, M.D.
Chairman of the Scientific Advisory Board
Xavier Jeunemaitre, M.D., Ph.D.
Shaine A. Morris, M.D., M.P.H.
Bart Loeys, M.D., Ph.D.
Peter Byers, M.D.
Living with VEDS
The Tays Family
Aytu BioPharma is a proud sponsor of these VEDS Advocacy Groups
1. https://www.clinicaltrials.gov/ct2/show/NCT00332202. 2. Bowen CJ et al. Targetable cellular signaling events mediate vascular pathology in vascular Ehlers-Danlos Syndrome. J Clin Invest. 2020 Feb 3;130(2):686-698.